Tokyo, Japan – April 24, 2026 – Craif Inc., a bio-AI startup dedicated to early cancer detection, announced the appointment of Takeo Mukai as Chief Financial Officer (CFO). A Japanese-American born in New York, Takeo Mukai brings extensive experience across finance, management, and the medical device industry, having served as CEO, COO, and CFO at multiple U.S. healthcare companies and led several successful exits. Through this appointment—an uncommon approach for a Japanese startup—Craif accelerates its non-linear growth on a global scale.
Craif is committed to solving the global challenge of making early cancer detection accessible to everyone. The company has been steadily building its presence in the United States—the world’s largest market and the global standard-setter in life sciences. In Japan, Craif’s business continues to grow, with its test now available at over 2,400 medical institutions and 5,000 drugstores, with publicly funded programs adopted by local governments. Against this backdrop, Craif has appointed Takeo Mukai to accelerate its expansion into the U.S. market as the next stage of growth.
In the U.S., Craif is collaborating with 30 medical institutions across 15 states, laying the groundwork for insurance reimbursement in early pancreatic cancer detection. Going forward, conducting large-scale clinical trials, executing major fundraising, advancing financial strategy, and building a strong corporate governance framework are all essential. These priorities demanded a leader with deep management experience in the U.S. healthcare market.